The combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) has been approved by the European Commission for the treatment of patients with unresectable or metastatic BRAF V600–positive melanoma, according to a statement from the drugs’ developer, Novartis.
MRV Research
Combination Therapies Continue to Advance in Melanoma
Both targeted therapy and immunotherapy regimens, as combinations, have shown significant benefit in the treatment of melanoma.
Combination treatment with the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib showed promise in patients with BRAFV600-positive advanced melanoma in both the BRIM7 and coBRIM studies.
In Cutaneous Melanoma, Early Sentinel-Node Biopsy Associated with Poorer Survival
Early sentinel-node biopsy is associated with poorer survival than delayed biopsy in patients with cutaneous melanoma, a study published this month in the European Journal of Cancer has shown.1
SciBase’s US Reader Study Shows Significant Improvement in Detection of Melanoma Using Nevisense
SciBase today announces the results from their Reader Study in the US. The results from the study show that the addition of Nevisense significantly improved the ability of US dermatologists to accurately detect melanoma. The Reader Study is an important requirement of the application process to the US Food and Drug Administration (FDA). With the results from the study, SciBase can now compile their complete application.